Effects of imidapril on left ventricular mass in chronic hemodialysis patients

Hypertension Research

Volumn 29, Issue 4, 2006, Pages 253-260

  Matsumoto, Nobuko ^a   Ishimitsu, Toshihiko ^a   Okamura, Atsushi ^a   Seta, Hotoshi ^a   Takahashi, Masaki ^a   Matsuoka, Hiroaki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Hemodialysis; Imidapril; Left ventricular hypertrophy

Indexed keywords

ALDOSTERONE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN II; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAPRIL; PLACEBO;

ADULT; AGE DISTRIBUTION; ALDOSTERONE BLOOD LEVEL; ANGIOTENSIN BLOOD LEVEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAINTENANCE THERAPY; MALE; PLASMA RENIN ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; BODY WEIGHT; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION, RENAL; HYPERTROPHY, LEFT VENTRICULAR; IMIDAZOLIDINES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PLACEBOS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 33744962268     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.29.253     Document Type: Article

References (54)

1. Collins AJ, Kasiske B, Herzog C, et al: Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States. Outcomes: hospitalization and mortality. Am J Kidney Dis 2005; 45 (1 Suppl 1): S117-S138.
2. Japanese Society for Dialysis Therapy: An overview of dialysis treatment in Japan (as of Dec. 31, 2003). J Jpn Soc Dial Ther 2005; 38: 1-16.
3. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in endstage renal disease. Kidney Int 1989; 36: 286-290.
4. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE: Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 1996; 11: 1277-1285.
5. Harnett JD, Kent GM, Barre PE, Taylor R, Parfrey PS: Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol 1994; 4: 1486-1490.
6. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996; 49: 1379-1385.
7. Washio M, Okuda S, Mizoue T, et al: Risk factors for left ventricular hypertrophy in chronic hemodialysis patients. Clin Nephrol 1997; 47: 362-366.
8. Zoccali C, Mallamaci F, Tripepi G, et al: Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients: CREED investigators. J Hypertens 1999; 17: 1751-1758.
9. Assanelli D, Cannella G, Guerra UP, Cumintti S, Gaggiotti M: Effects of intravascular volume loading and unloading on atrial sizes and left ventricular function in dialyzed uremic man. Am J Noninvas Cardiol 1990; 4: 53-59.
10. Brewster UC, Setaro JF, Perazella MA: The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 2003; 326: 15-24.
11. Struthers AD, MacDonald TM: Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004; 61: 663-670.
12. Diamond JA, Phillips RA: Hypertensive heart disease. Hypertens Res 2005; 28: 191-202.
13. Hayashi K, Nunami K, Kato J, et al: Studies on angiotensin converting enzyme inhibitors. 4. Synthesis and angiotensin converting enzyme inhibitory activities of 3-acyl-1-allcyl-2-oxoimidazolidine-4-carboxylic acid derivatives. J Med Chem 1989; 32: 289-297.
14. Hosoya K, Ishimitsu T: Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor. Cardiovasc Drug Rev 2002; 20: 93-110.
15. Comon PJ, Walshe JJ, Heinle SK, Minda S, Krucoff M, Schwab SJ: Predialysis systolic blood pressure correlates strongly with mean 24-hour systolic blood pressure and left ventricular mass in stable hemodialysis patients. J Am Soc Nephrol 1996; 7: 2658-2663.
16. Zoccali C, Mallamaci F, Tripepi G, et al: Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients: CREED investigators. J Hypertens 1999; 17: 1751-1758.
17. Devereux RB, Alonso DR, Lutas EM, et al: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458.
18. Kasahara Y, Ashihara Y: Colorimetry of angiotensin-I converting enzyme activity in serum. Clin Chem 1981; 27: 1922-1925.
19. Ishimitsu T, Tsukada K, Ohta S, et al: Increased cardiovascular risk in long-term hemodialysis patients carrying deletion allele of ACE gene polymorphism. Am J Kidney Dis 2004; 44: 466-475.
20. Nitta K, Akiba T, Uchida K, et al: Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis patients. Hypertens Res 2004; 27: 47-52.
21. Kawamura M, Fijimoto S, Hisanaga S, Yamamoto Y, Eto T: Incidence, outcome, and risk factors of cerebrovascular events in patients undergoing maintenance hemodialysis. Am J Kidney Dis 1998; 31: 991-996.
22. Cannella G, Paoletti E, Delfino R, Peloso G, Molinari S. Traverso GB: Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int 1993; 44: 881-886.
23. Lopez-Gomez JM, Verde E, Perez-Garcia R: Blood pressure, left ventricular hypertrophy and long-term prognosis in hemodialysis patients. Kidney Int Suppl 1998; 68: S92-S98.
24. Ozkahya M, Toz H, Qzerkan F, et al: Impact of volume control on left ventricular hypertrophy in dialysis patients. J Nephrol 2002; 15: 655-660.
25. Gunal AI, Karaca I, Aygen B, Yavuzkir M, Dogukan A, Celiker H: Strict fluid volume control and left ventricular hypertrophy in hypertensive patients on chronic haemodialysis: a cross-sectional study. J Int Med Res 2004; 32: 70-77.
26. Agarwal R, Lewis R, Davis IL, Becker B: Lisinopril therapy for hemodialysis hypertension: hemodynamic and endocrine responses. Am J Kidney Dis 2001; 38: 1245-1250.
27. Lins RL, Elseviers M, Rogiers P, et al: Importance of volume factors in dialysis related hypertension. Clin Nephrol 1997; 48: 29-33.
28. Ventura JE, Sposito M: Volume sensitivity of blood pressure in end-stage renal disease. Nephrol Dial Transplant 1997; 12: 485-491.
29. London GM, Pannier B, Guerin AP, Marchais SJ, Safar ME, Cuche JL: Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994; 90: 2786-2796.
30. Paoletti E, Cassottana P, Bellino D, Specchia C, Messa P, Cannella G: Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors. Am J Kidney Dis 2002; 40: 728-736.
31. Shibasaki Y, Masaki H, Nishiue T, Nishikawa M, Matsubara H, Iwasaka T: Angiotensin II type I receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 2002; 90: 256-261.
32. Kanno Y, Kaneko K, Kaneko M, et al: Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients. J Cardiovasc Pharmacol 2004; 43: 380-386.
33. Cannella G, Paoletti E, Delfino R, Peloso G, Rolla D, Molinari S: Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 1997; 30: 659-664.
34. Salem MM: Hypertension in the hemodialysis population: a survey of 649 patients. Am J Kidney Dis 1995; 26: 461-468.
35. Mittal SK, Kowalski E, Trenkle J, et al: Prevalence of hypertension in a hemodialysis population. Clin Nephrol 1999; 51: 77-82.
36. Grekas D, Bamichas G, Bacharaki D, Goutzaridis N, Kasimatis E, Tourkantonis A: Hypertension in chronic hemodialysis patients: current view on pathophysiology and treatment. Clin Nephrol 2000; 53: 164-168.
37. Lakkis J, Lu WX, Weir MR: RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep 2003; 5: 408-417.
38. Sato A, Saruta T: Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 2003; 16: 781-788.
39. Navar LG, Harrison-Bernard LM, Imig JD, Wang CT, Cervenka L, Mitchell KD: Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. J Am Soc Nephrol 1999; 10 (Suppl 12): S266-S272.
40. Delcayre C, Silvestre JS: Aldosterone and the heart: towards a physiological function? Cardiovasc Res 1999; 43: 7-12.
41. Davies E, MacKenzie SM: Extra-adrenal production of corticosteroids. Clin Exp Pharmacol Physiol 2003; 30: 437-445.
42. Takai S, Jin D, Sakaguchi M, Miyazaki M: Significant target organs for hypertension and cardiac hypertrophy by angiotensin-converting enzyme inhibitors. Hypertens Res 2004; 27: 213-219.
43. Kubo M, Ochiai T, Kato J, Ishida R: Pharmacological studies on TA-6366, a new ACE inhibitor: II. Effect of long-term administration from the pre-hypertensive stage on blood pressure, relative heart weight and ACE activity of various tissues in spontaneously hypertensive rats (SHRs). Jpn J Pharmacol 1991; 57: 517-526.
44. Saruta T, Arakawa K, Iimura O, et al: Difference in the incidence of cough induced by angiotensin converting enzyme inhibitors: a comparative study using imidapril hydrochloride and enalapril maleate. Hypertens Res 1999; 22: 197-202.
45. Knoll GA, Sahgal A, Nair RC, Graham J, van Walraven C, Burns KD: Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med 2002; 112: 110-114.
46. Hörl MP, Hörl WH: Drug therapy for hypertension in hemodialysis patients. Semin Dial 2004; 17: 288-294.
47. Akpolat T, Gumus T, Bedir A, Adam B: Acute effect of trandolapril on serum erythropoietin in uremic and hypertensive patients. J Nephrol 1998; 11: 94-97.
48. Erturk S, Ates K, Duman N, Karatan O, Erbay B, Ertug E: Unresponsiveness to recombinant human erythropoietin in haemodialysis patients: possible implications of angiotensin-converting enzyme inhibitors. Nephrol Dial Transplant 1996; 11: 396-397.
49. Nakao K, Shirakura T, Azuma M, Maekawa T: Studies on erythropoietic action of angiotensin II. Blood 1967; 29: 754-760.
50. Albitar S, Genin R, Fen-Chong M, Serveaux MO, Bourgeon B: High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 1206-1210.
51. Marathias KP, Agroyannis B, Mavromoustakos T, Matsoukas J, Vlahakos DV: Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Curr Top Med Chem 2004; 4: 483-486.
52. Sikole A, Polenakovic M, Spiroska V, Polenakovic B, Klinkmann H, Scigalla P: Recurrence of left ventricular hypertrophy following cessation of erythropoietin therapy. Artif Organs 2002; 26: 98-102.
53. Nishikimi T, Futoo Y, Tamano K, et al: Plasma brain natriuretic peptide levels in chronic hemodialysis patients: influence of coronary artery disease. Am J Kidney Dis 2001; 37: 1201-1208.
54. Mallamaci F, Zoccali C, Tripepi G, et al: Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 2001; 59: 1559-1566.